Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of KACM001 autologous lymphocyte injection plus S-1/oxaliplatin or cisplatin in advanced gastric cancer
CTR20232602Phase 2Active
- Sponsor
- Kangairuihao Biotechnology
- Start
- Sep 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of KACM001 autologous lymphocyte injection in gastric adenocarcinoma, sponsored by Kangairuihao Biotechnology. Started Sep 2023; status: active.
02
Drugs
KACM001 autologous lymphocyte injection
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on CTR20232602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232602.